My State LLC New Jersey Accelerator

New Jersey's pharmaceutical corridor along I-287 is the largest concentration of pharma R&D in the world — home to Johnson & Johnson, Merck, and hundreds of biotech companies that collectively employ more life sciences workers than California's Bay Area. For life sciences founders, this means a customer base, partnership network, and talent pool that's unmatched anywhere except Boston.

New Jersey's position between New York City and Philadelphia creates a natural B2B sales corridor — startups here can serve two top-5 US metro markets from a single headquarters, creating the market density of a coastal hub at a fraction of the cost.

New Jersey's startup ecosystem spans Princeton's research corridor and the Newark-Jersey City tech scene growing adjacent to New York City. Edison Partners (Princeton) and First Round Capital's NJ deals are the most active institutional bets locally. NJEDA's NJ Ignite program offers matching grants for co-working space for early-stage companies, and NJEDA manages a $500M venture fund of funds. Stevens Institute of Technology, NJIT, and Rutgers' new ventures programs generate deep-tech spinouts in materials science, AI, and energy. Jersey City's fintech ecosystem, positioned directly across from Lower Manhattan, is particularly strong — NJ's proximity to Wall Street and major banks creates accelerated sales cycles for B2B financial technology founders.

New Jersey LLCs pay a $125 formation fee and an annual report fee of $75 due in the anniversary month. New Jersey has no franchise tax on LLCs, but the state levies a minimum pass-through business alternative income tax (BAIT) of $375 annually. The state's graduated income tax (up to 10.75% — among the highest top rates in the US) applies to pass-through LLC income for high earners. New Jersey's sales tax (6.625%) applies to tangible goods and some digital products. The Angel Investor Tax Credit Program (10%–20% of qualifying investment) supports early-stage deal flow. The Technology Business Tax Certificate Transfer Program allows qualifying R&D companies to sell unused NOL credits — a meaningful source of non-dilutive capital for early-stage product companies.